Expanded access offers dupilumab to severe allergy patients
NCT ID NCT06631677
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This program provides continued dupilumab treatment to adults with severe IgE-mediated food allergy who previously received linvoseltamab and background dupilumab in an earlier study. The goal is to maintain disease control and manage allergic reactions. Only those who completed the parent study without serious side effects are eligible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOOD ALLERGY are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.